ONCAlert | Upfront Therapy for mRCC
Conference  >  2016 SITC Meeting  >  

Sonja Althammer Discusses Biomarkers for Durvalumab in Lung Cancer

Sonja Althammer, PhD
Published Online: 9:24 PM, Sat November 12, 2016

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond best to treatment with the PD-L1 inhibitor durvalumab.
Findings from the analysis were presented at the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting & Associated Programs. Overall, the combination of CD8+ and PD-L1+ densities correlated with response and improved overall survival with durvalumab.

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.